Anavex Life Sciences (AVXL) Total Current Liabilities (2012 - 2022)

Anavex Life Sciences' Total Current Liabilities history runs 11 years deep, the most recent figure standing at $9.5 million for Q2 2022.

• In Q2 2022, Total Current Liabilities changed N/A year-over-year to $9.5 million; the TTM figure through Jun 2022 stood at $9.5 million (changed N/A YoY), while the FY2021 annual figure was $10.8 million, up 47.81% from the prior year.
• Total Current Liabilities came in at $9.5 million for Q2 2022 at Anavex Life Sciences, up from $8.1 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $10.8 million in Q3 2021 to a low of $3.2 million in Q2 2018.
• A 5-year average of $6.6 million and a median of $6.4 million in 2019 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities jumped 120.62% in 2018 and slipped 2.23% in 2020, its largest moves.
• Anavex Life Sciences' Total Current Liabilities stood at $4.9 million in 2018, then increased by 12.06% to $5.5 million in 2019, then surged by 47.03% to $8.0 million in 2020, then jumped by 31.06% to $10.5 million in 2021, then slipped by 9.92% to $9.5 million in 2022.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $9.5 million, $8.1 million, and $10.5 million for Q2 2022, Q1 2022, and Q4 2021 respectively.

Peer Comparison